Physician profile
Douglas Heiner
NPI 1366753865
$2,950.10
in general payments reported to CMS, 2019-2025
23 companies · $733 in 2025
The $733 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $237 · 2021: $150 · 2022: $353 · 2023: $507 · 2024: $639 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.30 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $585.66 | 2019-2025 | |
| Abbvie INC. | $457.23 | 2019-2024 | |
| Janssen Biotech, INC. | $412.23 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $334.33 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $187.54 | 2022-2025 | Dupixent, Libtayo |
| Ucb, INC. | $154.34 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $138.57 | 2021-2025 | Anzupgo |
| Lilly USA, LLC | $114.78 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Allergan, INC. | $113.12 | 2020 | |
| Amgen INC. | $67.62 | 2019-2025 | Otezla, Otezla |
| Almirall LLC | $55.50 | 2019-2022 | |
| Incyte Corporation | $53.13 | 2023-2025 | Opzelura |
| Pfizer INC. | $51.55 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $46.07 | 2023 | Sotyktu |
| Genzyme Corporation | $33.62 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $28.01 | 2019 | |
| Botanix Sb INC | $21.20 | 2025 | Sofdra |
| Celgene Corporation | $19.95 | 2019 | |
| Sandoz INC. | $19.88 | 2025 | Hyrimoz |
| Mayne Pharma Commercial LLC | $16.70 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.27 | 2019 | |
| Galderma Laboratories, L.P. | $12.37 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Heiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.